/ENTA
ENTA Stock - Enanta Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$15.39+5.92%
+$0.86 (+5.92%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+30.0%upside
Target: $20.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.24 – $15.54
TARGET (TP)$20.00
STOP LOSS$14.16
RISK/REWARD1:3.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.97
52W High$15.86
52W Low$4.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M |
| Gross Profit | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-85,349,000 | $-121,691,000 | $-137,207,000 | $-123,844,000 | $-109,573,000 |
| Net Income | $-81,889,000 | $-116,045,000 | $-133,816,000 | $-121,755,000 | $-78,996,000 |
| Net Margin | -125.4% | -171.6% | -169.0% | -141.3% | -81.4% |
| EPS | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 |
Company Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
80%
Hold / Neutral
1
20%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish1 Neutral/Bearish
Price Targets
$33
Average Target
↑ 112.6% Upside
Now
$14
Low
$33
Average
$62
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2025 | JP Morgan | Initiation | Overweight | - |
| October 1st 2025 | Jefferies | Upgrade | Buy | $20 |
| July 28th 2025 | H.C. Wainwright | Resumed | Buy | $20 |
| August 9th 2023 | JP Morgan | Downgrade | Underweight | $14 |
| August 8th 2023 | Jefferies | Downgrade | Hold | $18← $49 |
| December 9th 2022 | H.C. Wainwright | Initiation | Buy | $56 |
| July 6th 2022 | Evercore ISI | Upgrade | Outperform | $62 |
| June 1st 2022 | Evercore ISI | Upgrade | In-line | $39 |
Earnings History & Surprises
ENTABeat Rate
61%
Last 18 quarters
Avg Surprise
+3.8%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-0.87
Q4 2025
EPS Surprise History
Q1 24
-33.9%
$-1.58vs$-1.18
Q2 24
-16.7%
$-1.47vs$-1.26
Q3 24
+28.2%
$-1.07vs$-1.49
Q4 24
-17.2%
$-1.36vs$-1.16
Q1 25
+9.5%
$-1.05vs$-1.16
Q2 25
-1.9%
$-1.06vs$-1.04
Q3 25
+32.0%
$-0.85vs$-1.25
Q4 25
+23.0%
$-0.87vs$-1.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $-0.54 | — | — | — |
Q4 2025 | Nov 17, 2025 | $-1.13 | $-0.87 | +23.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.25 | $-0.85 | +32.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-1.04 | $-1.06 | -1.9% | ✗ MISS |
Q1 2025 | Feb 10, 2025 | $-1.16 | $-1.05 | +9.5% | ✓ BEAT |
Q4 2024 | Nov 25, 2024 | $-1.16 | $-1.36 | -17.2% | ✗ MISS |
Q3 2024 | Aug 5, 2024 | $-1.49 | $-1.07 | +28.2% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-1.26 | $-1.47 | -16.7% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $-1.18 | $-1.58 | -33.9% | ✗ MISS |
Q4 2023 | Nov 20, 2023 | $-2.11 | $-1.33 | +37.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-2.38 | $-1.86 | +21.8% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-1.91 | $-1.79 | +6.3% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $-1.52 | $-1.39 | +8.6% | ✓ BEAT |
Q4 2022 | Nov 21, 2022 | $-1.37 | $-1.27 | +7.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.36 | $-1.53 | -12.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-1.43 | $-1.63 | -14.0% | ✗ MISS |
Q1 2022 | Feb 8, 2022 | $-1.13 | $-1.48 | -31.0% | ✗ MISS |
Q4 2021 | Nov 22, 2021 | $-1.31 | $-1.22 | +6.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-1.41 | $-1.19 | +15.6% | ✓ BEAT |
Latest News
Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate
➖ NeutralBenzinga•Nov 17, 2025, 09:02 PM
JP Morgan Initiates Coverage On Enanta Pharma with Overweight Rating, Announces Price Target of $17
📈 PositiveBenzinga•Nov 14, 2025, 12:28 PM
Enanta Pharmaceuticals Highlights Promising Zelicapavir Pediatric Results And EDP-323 Post-Exposure Prophylaxis Data For RSV At IDWeek 2025
📈 PositiveBenzinga•Oct 20, 2025, 11:04 AM
Enanta Pharmaceuticals to Showcase RSV Drug Data at IDWeek 2025, Highlighting Two Oral Once-Daily Treatments
📈 PositiveBenzinga•Oct 7, 2025, 11:14 AM
Jefferies Upgrades Enanta Pharma to Buy, Raises Price Target to $20
📈 PositiveBenzinga•Oct 1, 2025, 04:27 PM
Reported Earlier, Enanta Pharmaceuticals Prices Upsized Public Offering Of 6.5M Common Shares At $10.00 Each, Targeting $65M Gross Proceeds
➖ NeutralBenzinga•Oct 1, 2025, 05:57 AM
Enanta Pharmaceuticals shares are trading lower after the company announced a $50 million public offering.
📉 NegativeBenzinga•Sep 30, 2025, 08:23 PM
Enanta Pharmaceuticals falls on public offering of common stock
📉 NegativeSeeking Alpha•Sep 30, 2025, 08:18 PM
Enanta Pharma Commences $50M Public Offering
➖ NeutralBenzinga•Sep 30, 2025, 08:13 PM
Enanta Pharma Commences $50M Public Offering With Option To Sell Additional $7.5M In Common Stock
➖ NeutralBenzinga•Sep 30, 2025, 08:13 PM
WestPark Capital Maintains Buy on Enanta Pharma, Raises Price Target to $28
📈 PositiveBenzinga•Sep 30, 2025, 12:01 PM
Enanta Pharmaceuticals shares are trading higher after the company reported topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults.
📈 PositiveBenzinga•Sep 29, 2025, 04:09 PM
Enanta Pharma Reports Topline Data From RSVHR, Phase 2b Study To Evaluate Efficacy And Safety Of Zelicapavir In Outpatient Adults With Acute RSV Infection
➖ NeutralBenzinga•Sep 29, 2025, 10:33 AM
Enanta Pharmaceuticals shares are trading higher after the company announced it will present topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults on Monday.
📈 PositiveBenzinga•Sep 26, 2025, 08:03 PM
Enanta Pharma To Share Topline Results From RSVHR, Phase 2b Study Evaluating Zelicapavir For Treatment Of RSV In High-Risk Adults, On Sept 29
➖ NeutralBenzinga•Sep 26, 2025, 08:02 PM
Evercore ISI Group Maintains Outperform on Enanta Pharma, Lowers Price Target to $12
➖ NeutralBenzinga•Sep 15, 2025, 01:50 PM
WestPark Capital Initiates Coverage On Enanta Pharma with Buy Rating, Announces Price Target of $24
📈 PositiveBenzinga•Sep 2, 2025, 11:26 AM
Enanta Pharmaceuticals Appoints Harry R. Trout As Interim Principal Financial Officer
➖ NeutralBenzinga•Aug 27, 2025, 09:01 PM•Also:
Frequently Asked Questions about ENTA
What is ENTA's current stock price?
Enanta Pharmaceuticals, Inc. (ENTA) is currently trading at $15.39 per share. The stock has moved +5.92% today.
What is the analyst price target for ENTA?
The average analyst price target for ENTA is $20.00, based on 1 analyst.
What sector is Enanta Pharmaceuticals, Inc. in?
Enanta Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ENTA's market cap?
Enanta Pharmaceuticals, Inc. has a market capitalization of $0.33 billion, making it a small-cap company.
Does ENTA pay dividends?
No, Enanta Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASMB
Assembly Biosciences, Inc.
$35.26
Mkt Cap: $0.3B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
IMRX
Immuneering Corporation
$5.65
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
VYGR
Voyager Therapeutics, Inc.
$4.00
Mkt Cap: $0.2B
Explore stocks similar to ENTA for comparison